Recent, as yet fragmentary evidence suggests that intervention with GLP1-RA, e.g., liraglutide, may reduce body weight and improve hyperandrogenism and menstrual irregularities in women with obesity and PCOS 28,29,30,31,32
Eli Lilly has amassed a USD 1.5 billion pre-launch inventory of its oral weight loss drug orforglipron ahead of FDA decision, representing a decisive effort to avoid repeating supply constraints [4]
[3] mhra.gov.uk)
The risks of doing so including infection, incorrect dosing, and adverse reactions without medical support are substantial
If you do not, tirzepatide is the closest approved alternative and it is producing results that were not possible from any drug a few years ago
Zander, M., Madsbad, S., Madsen, J